메뉴 건너뛰기




Volumn 6, Issue 1, 2018, Pages

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 2 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; LIXISENATIDE; TEDUGLUTIDE;

EID: 85041396051     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2017-000475     Document Type: Article
Times cited : (30)

References (24)
  • 1
    • 84992358035 scopus 로고    scopus 로고
    • The cardiovascular biology of glucagon-like peptide-1
    • Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016;24:15-30.
    • (2016) Cell Metab , vol.24 , pp. 15-30
    • Drucker, D.J.1
  • 2
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
    • (2016) N Engl J Med , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 3
    • 84994813253 scopus 로고    scopus 로고
    • Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
    • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44.
    • (2016) N Engl J Med , vol.375 , pp. 1834-1844
    • Marso, S.P.1    Bain, S.C.2    Consoli, A.3
  • 4
    • 85030448557 scopus 로고    scopus 로고
    • Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
    • Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228-39.
    • (2017) N Engl J Med , vol.377 , pp. 1228-1239
    • Holman, R.R.1    Bethel, M.A.2    Mentz, R.J.3
  • 5
    • 84948740668 scopus 로고    scopus 로고
    • Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
    • Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
    • (2015) N Engl J Med , vol.373 , pp. 2247-2257
    • Pfeffer, M.A.1    Claggett, B.2    Diaz, R.3
  • 6
    • 85028547742 scopus 로고    scopus 로고
    • Liraglutide and renal outcomes in type 2 diabetes
    • Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839-48.
    • (2017) N Engl J Med , vol.377 , pp. 839-848
    • Mann, J.F.E.1    Ørsted, D.D.2    Brown-Frandsen, K.3
  • 7
    • 84898919428 scopus 로고    scopus 로고
    • The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy
    • Varadhan L, Humphreys T, Walker AB, et al. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract 2014;103:e37-e39.
    • (2014) Diabetes Res Clin Pract , vol.103 , pp. e37-e39
    • Varadhan, L.1    Humphreys, T.2    Walker, A.B.3
  • 8
    • 85019559864 scopus 로고    scopus 로고
    • GLP-1R as a target for the treatment of diabetic retinopathy: Friend or foe?
    • Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes 2017;66:1453-60.
    • (2017) Diabetes , vol.66 , pp. 1453-1460
    • Simó, R.1    Hernández, C.2
  • 9
    • 84962147366 scopus 로고    scopus 로고
    • Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
    • Hernández C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 2016;65:172-87.
    • (2016) Diabetes , vol.65 , pp. 172-187
    • Hernández, C.1    Bogdanov, P.2    Corraliza, L.3
  • 10
    • 85026802542 scopus 로고    scopus 로고
    • Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes
    • Hernández C, Bogdanov P, Solà-Adell C, et al. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia 2017;60:2285-98.
    • (2017) Diabetologia , vol.60 , pp. 2285-2298
    • Hernández, C.1    Bogdanov, P.2    Solà-Adell, C.3
  • 11
    • 85026922718 scopus 로고    scopus 로고
    • Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-Analysis of randomized controlled trials
    • Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-Analysis of randomized controlled trials. Acta Diabetol 2017;54:933-41.
    • (2017) Acta Diabetol , vol.54 , pp. 933-941
    • Dicembrini, I.1    Nreu, B.2    Scatena, A.3
  • 12
    • 85025080031 scopus 로고    scopus 로고
    • Reality and truth: Balancing the hope and the hype of real-world evidence
    • Patel A, Billot L, Reality BL. Reality and truth: balancing the hope and the hype of real-world evidence. Circulation 2017;136:260-2.
    • (2017) Circulation , vol.136 , pp. 260-262
    • Patel, A.1    Billot, L.2    Reality, B.L.3
  • 13
    • 85024835007 scopus 로고    scopus 로고
    • SGTL2 inhibitors and amputations in the US FDA adverse event reporting system
    • Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol 2017;5:680-1.
    • (2017) Lancet Diabetes Endocrinol , vol.5 , pp. 680-681
    • Fadini, G.P.1    Avogaro, A.2
  • 14
    • 85023777061 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
    • (2017) N Engl J Med , vol.377 , pp. 644-657
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3
  • 15
    • 34447520376 scopus 로고    scopus 로고
    • Novel statistical tools for monitoring the safety of marketed drugs
    • Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007;82:157-66.
    • (2007) Clin Pharmacol Ther , vol.82 , pp. 157-166
    • Almenoff, J.S.1    Pattishall, E.N.2    Gibbs, T.G.3
  • 16
    • 84978372329 scopus 로고    scopus 로고
    • Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data
    • Sarangdhar M, Tabar S, Schmidt C, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol 2016;34:697-700.
    • (2016) Nat Biotechnol , vol.34 , pp. 697-700
    • Sarangdhar, M.1    Tabar, S.2    Schmidt, C.3
  • 17
    • 2642668188 scopus 로고
    • Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study
    • The Kroc Collaborative Study Group. The Kroc Collaborative Study Group
    • The Kroc Collaborative Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. JAMA 1988;260:37-41.
    • (1988) JAMA , vol.260 , pp. 37-41
  • 18
    • 85041694897 scopus 로고    scopus 로고
    • Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
    • Epub ahead of print 27 Nov 2017
    • Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2017. 10.1111/dom.13172 (Epub ahead of print 27 Nov 2017).
    • (2017) Diabetes Obes Metab
    • Vilsbøll, T.1    Bain, S.C.2    Leiter, L.A.3
  • 19
    • 85019269077 scopus 로고    scopus 로고
    • SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA adverse event reporting system
    • Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 2017;60:1385-9.
    • (2017) Diabetologia , vol.60 , pp. 1385-1389
    • Fadini, G.P.1    Bonora, B.M.2    Avogaro, A.3
  • 20
    • 69549088241 scopus 로고    scopus 로고
    • Regression from prediabetes to normal glucose regulation in the diabetes prevention program
    • Perreault L, Kahn SE, Christophi CA, et al. Regression from prediabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009;32:1583-8.
    • (2009) Diabetes Care , vol.32 , pp. 1583-1588
    • Perreault, L.1    Kahn, S.E.2    Christophi, C.A.3
  • 21
    • 0037097039 scopus 로고    scopus 로고
    • Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial
    • Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
    • (2002) Lancet , vol.359 , pp. 2072-2077
    • Chiasson, J.L.1    Josse, R.G.2    Gomis, R.3
  • 22
    • 84936166069 scopus 로고    scopus 로고
    • A randomized, controlled trial of 3.0 mg of liraglutide in weight management
    • Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.
    • (2015) N Engl J Med , vol.373 , pp. 11-22
    • Pi-Sunyer, X.1    Astrup, A.2    Fujioka, K.3
  • 23
    • 84858414156 scopus 로고    scopus 로고
    • Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: Retrospective analysis
    • Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: Retrospective analysis. BMJ 2012;344:e874.
    • (2012) BMJ , vol.344 , pp. e874
    • Thomas, R.L.1    Dunstan, F.2    Luzio, S.D.3
  • 24
    • 85021835588 scopus 로고    scopus 로고
    • Sodium-glucose co-Transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature
    • Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-Transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab 2018;20.
    • (2018) Diabetes Obes Metab , pp. 20
    • Bonora, B.M.1    Avogaro, A.2    Fadini, G.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.